Opinion|Videos|July 22, 2024
Biologic Therapies for Hidradenitis Suppurativa
Author(s)Vivian Shi, MD, FAAD
A dermatologist outlines the role for biologic therapies in the hidradenitis suppurativa treatment landscape and discusses the importance of early intervention.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What is the “window of opportunity” with anti-inflammatory treatments in HS and why is early intervention with biologic therapies so imperative?
- Which biologic therapies are currently used in HS and what are the important patient considerations you consider before utilizing these?
Advertisement
Related to this article
AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.
A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.
Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
3
Disability, Economic Toll of Multimorbidity Climb in Older Adults
4
The Next Decade of Cancer Care Is Coming Home: Who Will Be in the Driver’s Seat?
5